Aurinia Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AUPH Aurinia Pharmaceuticals Inc
UNH UnitedHealth Group Inc
BAC Bank of America Corp
WSO Watsco Inc
LITB LightInTheBox Holding Co Ltd
CVCY Central Valley Community Bancorp
AFAQU AF Acquisition Corp
HCIIW Hudson Executive Investment Equity II Warrant Exp 31 Jan 2027 *W EXP 01/31/2027
MEDS TRxADE Health Inc
HCICW Hennessy Capital Investment V Equity Warrant Exp 15 Jan 2025 *W EXP 01/15/2025
Go

Health Care : Biotechnology | Small Cap Growth
Based in Canada
Company profile

Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

Closing Price
$11.45
Day's Change
0.46 (4.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.63
Day's Low
10.93
Volume
(Light)
Volume:
2,020,476

10-day average volume:
3,133,032
2,020,476
  • Prev Close
    10.99
  • Today's Open
    11.19
  • Day's Range
    10.93-11.63
  • Avg Vol (10-day)
    3.1M
  • Last (time)
    4:00p ET 05/17/22
  • Last (size)
    1
  • 52-Wk Range
    8.86 - 33.97
    LowHigh
  • (11/03/21 - 05/09/22)
    29.23%
  • 96.6%
  • Market Cap
    1.6B
  • Shares Outstanding
    141.7M
  • -1.27
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.1
  • 26.58
  • (% of float 04/29/22)
    8.88

Latest News

May 17, 2022
11:59 pm ET
Accesswire
11:55 pm ET
PR Newswire
6:48 pm ET
Accesswire
5:49 pm ET
Globe Newswire
11:02 am ET
Accesswire
5:45 am ET
PR Newswire
May 16, 2022
4:45 pm ET
Accesswire
3:46 pm ET
Newsfile
11:00 am ET
Accesswire
9:40 am ET
Accesswire
8:47 am ET
Newsfile
7:17 am ET
BusinessWire
5:45 am ET
PR Newswire
May 15, 2022
2:01 pm ET
Accesswire
11:16 am ET
PR Newswire
May 14, 2022
6:21 pm ET
Newsfile
May 13, 2022
9:00 pm ET
Globe Newswire
9:00 pm ET
Globe Newswire
7:15 pm ET
BusinessWire
6:00 pm ET
Newsfile
11:03 am ET
Accesswire
10:30 am ET
Accesswire
9:59 am ET
Newsfile
5:45 am ET
PR Newswire
4:52 am ET
PR Newswire
May 12, 2022
10:04 pm ET
Newsfile
8:34 pm ET
Globe Newswire
12:30 pm ET
Accesswire
11:57 am ET
Globe Newswire
5:45 am ET
PR Newswire
May 11, 2022
9:04 pm ET
Newsfile
7:27 pm ET
PR Newswire
11:01 am ET
Accesswire
9:31 am ET
Accesswire
9:01 am ET
Newsfile
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.